New Oral Weight Loss Pill Approved, Game-Changer for Aussies

0:00It's April 2nd, I'm Cory with the story, and this is Sydney News today, your AI-powered local news. US regulators just greenlit Eli Lilly's new daily pill for weight loss, called Orforglypron, and branded Foundaio stateside. It's an oral take on those ozempic-style GLP-1 drugs, no needles needed. Australian clinics like Mosh, my weight loss clinic, and eucalyptus are hyped, waiting on their own therapeutic goods administration to approve it. In trials, folks dropped 12% of body weight over 72 weeks, or 15% in a shorter 36-week run. Lilly kicks off sales, April 6th, through direct delivery, at $149 a month for the starter dose, matching rival Novo. Nordisk's new oral wegaby pill. Local bosses say this could hook more Aussie-scared-of-shots, plus it skips cold stores for easier shipping to remote spots and longer shelf life. Mosh's team calls it a game-changer for sticking with treatment long-term.

1:01Eucalyptus plans to stock it alongside oral wegaby, once it lands down under, noting fewer rules on when to take it, any time, with or without food, Lilly's pushing approvals in over 40 countries this year, and their shares jump 6% on the news. Pills like these won't fully swap out injections, which pack more punch, but experts figure they'll snag about 20% of the market by 20. 30. Watch for how demand plays out against mild gut side effects in that thyroid tumor warning.